[go: up one dir, main page]

SG11201803653QA - Inhibitors of ret - Google Patents

Inhibitors of ret

Info

Publication number
SG11201803653QA
SG11201803653QA SG11201803653QA SG11201803653QA SG11201803653QA SG 11201803653Q A SG11201803653Q A SG 11201803653QA SG 11201803653Q A SG11201803653Q A SG 11201803653QA SG 11201803653Q A SG11201803653Q A SG 11201803653QA SG 11201803653Q A SG11201803653Q A SG 11201803653QA
Authority
SG
Singapore
Prior art keywords
ret
inhibitors
Prior art date
Application number
SG11201803653QA
Inventor
Jason Brubaker
Joseph Kim
Kevin Wilson
Douglas Wilson
Lucian Dipietro
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of SG11201803653QA publication Critical patent/SG11201803653QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201803653QA 2015-11-02 2016-11-01 Inhibitors of ret SG11201803653QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249784P 2015-11-02 2015-11-02
US201662367960P 2016-07-28 2016-07-28
PCT/US2016/059879 WO2017079140A1 (en) 2015-11-02 2016-11-01 Inhibitors of ret

Publications (1)

Publication Number Publication Date
SG11201803653QA true SG11201803653QA (en) 2018-05-30

Family

ID=57286889

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803653QA SG11201803653QA (en) 2015-11-02 2016-11-01 Inhibitors of ret

Country Status (31)

Country Link
US (5) US10030005B2 (en)
EP (3) EP3371171B1 (en)
JP (3) JP6807385B2 (en)
KR (1) KR20180073689A (en)
CN (2) CN108473468B (en)
AU (1) AU2016348402B2 (en)
BR (1) BR112018008877B1 (en)
CA (1) CA3003721C (en)
CL (1) CL2018001181A1 (en)
DK (1) DK3371171T3 (en)
EA (1) EA038890B1 (en)
ES (1) ES2969185T3 (en)
FI (1) FI3371171T3 (en)
FR (1) FR24C1016I1 (en)
HR (1) HRP20231681T1 (en)
HU (1) HUE064659T2 (en)
IL (3) IL302209B2 (en)
LT (1) LT3371171T (en)
MX (1) MX384884B (en)
MY (1) MY194262A (en)
NZ (1) NZ742351A (en)
PH (1) PH12018500907A1 (en)
PL (1) PL3371171T3 (en)
PT (1) PT3371171T (en)
RS (1) RS65069B1 (en)
SA (1) SA518391496B1 (en)
SG (1) SG11201803653QA (en)
SI (1) SI3371171T1 (en)
TW (2) TWI787018B (en)
WO (1) WO2017079140A1 (en)
ZA (1) ZA201803050B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012029405B1 (en) 2010-05-20 2021-01-05 Array Biopharma Inc. macrocyclic compounds such as trk kinase inhibitors, pharmaceutical composition, use of a compound of formula i or a pharmaceutically acceptable salt thereof, process for the preparation of a compound
PL2872491T3 (en) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
RS57542B1 (en) 2013-10-17 2018-10-31 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
PL3395814T3 (en) 2013-10-25 2022-08-22 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
DK3322706T3 (en) 2015-07-16 2021-02-01 Array Biopharma Inc SUBSTITUTED PYRAZOLO [1,5-A] PYRIDINE COMPOUNDS AS RIGHT CHINESE INHIBITORS
MX2018001032A (en) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compounds useful for treating disorders related to kit and pdgfr.
EP3341374A1 (en) 2015-08-26 2018-07-04 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
MY194262A (en) 2015-11-02 2022-11-25 Blueprint Medicines Corp Inhibitors of ret
MX2018006195A (en) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk.
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
FI3442977T3 (en) 2016-04-15 2023-09-26 Blueprint Medicines Corp Inhibitors of activin receptor-like kinase
MX2018013885A (en) 2016-05-13 2019-08-16 Inst De Medicina Molecular Joaeo Lobo Antunes Methods of treating diseases associated with ilc3 cells.
WO2018017983A1 (en) * 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) * 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JP6888101B2 (en) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolo [1,5-a] pyrazine compounds as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN110891573A (en) * 2017-05-15 2020-03-17 缆图药品公司 Combinations of RET inhibitors and MTORC1 inhibitors and their use for treating cancers mediated by aberrant RET activity
TWI812649B (en) 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
US11236086B2 (en) 2017-10-18 2022-02-01 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
TW201932464A (en) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CR20200522A (en) * 2018-04-03 2021-02-17 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation EGFR MUTANT CANCER TREATMENT
WO2020035065A1 (en) * 2018-08-17 2020-02-20 南京明德新药研发有限公司 Pyrazole derivative as ret inhibitor
JP2022500383A (en) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Condensed heterocyclic compound as a RET kinase inhibitor
CN111285875B (en) * 2018-12-06 2023-02-03 苏州信诺维医药科技股份有限公司 Heterocyclic compound, application thereof and pharmaceutical composition containing same
CN111285882B (en) * 2018-12-07 2022-12-02 四川科伦博泰生物医药股份有限公司 Fused ring compound, pharmaceutical composition containing same, and preparation method and application thereof
CN111484479B (en) * 2019-01-25 2023-06-13 四川科伦博泰生物医药股份有限公司 Azacyclic compounds, pharmaceutical compositions containing the same, and methods of making and using the same
CN111499613B (en) * 2019-01-31 2023-05-12 浙江海正药业股份有限公司 N-carboxamide derivatives, method for the production thereof and their use in medicine
JP7615056B2 (en) 2019-02-19 2025-01-16 スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド Heterocyclic compounds, pharmaceutical compositions containing same, methods for their preparation and use
EP3950688B1 (en) * 2019-04-03 2025-01-15 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Nitrogen-containing spiro derivative as ret inhibitor
EP3856341B1 (en) 2019-04-12 2023-09-06 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
CN111808077B (en) * 2019-04-12 2023-05-02 浙江海正药业股份有限公司 Piperazine amide derivatives, process for their preparation and their use in medicine
CN111961034A (en) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 Compounds as RET kinase inhibitors and their applications
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity
CN113121524B (en) 2019-12-31 2023-04-25 南京创济生物医药有限公司 Heterocyclic sulfoxide imine compound, intermediate thereof, preparation method and application
CN113135896B (en) * 2020-01-18 2024-12-06 正大天晴药业集团股份有限公司 Methylpyrazole derivatives as RET inhibitors
CN111362923A (en) * 2020-03-25 2020-07-03 魏威 Method for preparing RET inhibitor pracetib, intermediate of pracetib and preparation method of pracetib
CN111440151A (en) * 2020-03-25 2020-07-24 魏威 Method for preparing antitumor drug prasutinib
CN111269229B (en) * 2020-03-27 2021-02-12 苏州信诺维医药科技有限公司 Compound for treating cancer
EP4155304A4 (en) * 2020-05-20 2024-05-29 TYK Medicines Inc. COMPOUND USED AS RET KINASE INHIBITOR AND ITS APPLICATION
MX2022015022A (en) * 2020-05-29 2023-03-08 Blueprint Medicines Corp Pralsetinib pharmaceutical compositions.
KR20230017234A (en) 2020-05-29 2023-02-03 블루프린트 메디신즈 코포레이션 Solid forms of pralcetinib
CN111777595A (en) * 2020-07-22 2020-10-16 上海希迈医药科技有限公司 Novel crystal form of cyclohexane carboxamide compound and preparation method thereof
WO2022086899A1 (en) 2020-10-19 2022-04-28 Teva Pharmaceuticals International Gmbh Solid state forms of pralsetinib and process for preparation thereof
WO2022117448A1 (en) 2020-12-03 2022-06-09 Sandoz Ag Crystalline forms of pralsetinib
CN116724024A (en) 2020-12-04 2023-09-08 缆图药品公司 Process for preparing platinib
CN113072541B (en) * 2021-04-02 2022-07-08 山东四环药业股份有限公司 Preparation method of targeted drug BLU-667
WO2022254255A1 (en) 2021-06-03 2022-12-08 Fundacao D. Anna De Sommerchampalimaud E Dr. Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
TW202345806A (en) 2022-03-31 2023-12-01 美商艾伯維有限公司 Thiazolo[5,4-b]pyridine malt-1 inhibitors
CN115057822B (en) * 2022-07-14 2023-05-02 上海优合贝德医药科技有限公司 New synthesis method of platinib intermediate 2097133-31-6
CN117466901A (en) * 2022-07-23 2024-01-30 浙江海正药业股份有限公司 Crystal forms of piperazinamide derivatives and their preparation methods and uses
KR20250052364A (en) 2022-08-24 2025-04-18 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
IT202300006819A1 (en) 2023-04-06 2024-10-06 Olon Spa PROCESS FOR PREPARING PRALSETINIB IN AMORPHOUS FORM, AND RELATED INTERMEDIATES IN CRYSTALLINE FORM.
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
BR0312873A (en) 2002-07-24 2005-06-28 Univ Cincinnati 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] benzamide for treating diseases associated with mutant retinase
PT1696920E (en) 2003-12-19 2015-01-14 Plexxikon Inc Compounds and methods for development of ret modulators
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20100047777A1 (en) 2005-05-26 2010-02-25 The Johns Hopkins University Methods for identifying mutations in coding and non-coding dna
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP1978958A4 (en) 2006-01-24 2009-12-02 Merck & Co Inc Ret tyrosine kinase inhibition
US20090048214A1 (en) * 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
AU2008273889B2 (en) 2007-07-09 2012-03-08 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EP2178861B1 (en) 2007-07-19 2014-08-20 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
WO2009018415A1 (en) * 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
WO2010006432A1 (en) 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
CA2755953A1 (en) 2009-03-24 2010-09-30 Vertex Pharmaceuticals Incorporated Novel aminopyridine derivatives having aurora a selective inhibitory action
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc Benzyl substituted triazine derivatives and their therapeutical applications
EA201290255A1 (en) 2009-10-30 2013-04-30 Ариад Фармасьютикалз, Инк. METHODS AND COMPOSITIONS FOR CANCER TREATMENT
KR101663637B1 (en) 2009-11-13 2016-10-07 제노스코 Kinase inhibitors
US9216172B2 (en) 2011-08-04 2015-12-22 National Cancer Center Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
AU2012298884B2 (en) 2011-08-23 2017-11-16 Foundation Medicine, Inc. Novel KIF5B-RET fusion molecules and uses thereof
MX370814B (en) 2011-09-02 2020-01-08 Univ California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof.
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
JP2015109806A (en) 2012-03-22 2015-06-18 アステラス製薬株式会社 Method for detecting new ret fused body
JP6175672B2 (en) * 2012-04-25 2017-08-09 ラクオリア創薬株式会社 Pyrrolopyridinone derivatives as TTX-S blockers
JP2015516439A (en) 2012-05-10 2015-06-11 シンタ ファーマシューティカルズ コーポレーション Treating cancer with Hsp90-inhibiting compounds
PL2872491T3 (en) 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
CN104619841A (en) 2012-07-26 2015-05-13 日本国立癌症研究中心 Fusion gene of CEP55 gene and RET gene
US20150238477A1 (en) 2012-09-07 2015-08-27 Exelixis, Inc. Method of Treating Lung Adenocarcinoma
HK1210427A1 (en) * 2012-09-25 2016-04-22 中外制药株式会社 Ret inhibitor
CN108047219A (en) 2012-11-07 2018-05-18 内尔维阿诺医学科学有限公司 Substituted pyrimidine radicals and Pyridylpyrrole and pyridinone, its preparation method and its purposes as kinase inhibitor
TWI629266B (en) 2012-12-28 2018-07-11 藍印藥品公司 Inhibitors of the fibroblast growth factor receptor
KR20150121712A (en) 2013-02-25 2015-10-29 브리스톨-마이어스 스큅 컴퍼니 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
MX2015012286A (en) 2013-03-15 2016-05-31 Glaxosmithkline Ip Dev Ltd Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors.
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
US20150057335A1 (en) 2013-08-20 2015-02-26 National Cancer Center Novel fusion genes identified in lung cancer
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
RS57542B1 (en) 2013-10-17 2018-10-31 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
PL3395814T3 (en) 2013-10-25 2022-08-22 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CR20170094A (en) 2014-09-10 2017-05-08 Glaxosmithkline Ip Dev Ltd NEW COMPOUNDS AS REORGANIZED INHIBITORS DURING TRANSFECTION (RET)
MA40581A (en) 2014-09-10 2019-04-10 Glaxosmithkline Ip Dev Ltd PYRIDONE DERIVATIVES USED AS REARRANGED KINASE INHIBITORS DURING TRANSFECTION (RET)
US10221181B2 (en) 2014-11-14 2019-03-05 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
DK3322706T3 (en) 2015-07-16 2021-02-01 Array Biopharma Inc SUBSTITUTED PYRAZOLO [1,5-A] PYRIDINE COMPOUNDS AS RIGHT CHINESE INHIBITORS
MX2018001032A (en) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compounds useful for treating disorders related to kit and pdgfr.
EP3341374A1 (en) 2015-08-26 2018-07-04 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN105255927B (en) 2015-09-30 2018-07-27 温州医科大学附属第一医院 A kind of KIAA1217-RET fusions
SG11201803009VA (en) 2015-11-02 2018-05-30 Five Prime Therapeutics Inc Cd80 extracellular domain polypeptides and their use in cancer treatment
MY194262A (en) 2015-11-02 2022-11-25 Blueprint Medicines Corp Inhibitors of ret
EP3371220A2 (en) 2015-11-02 2018-09-12 Janssen Pharmaceutica NV Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
MX2018006195A (en) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk.
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
CN109069512B (en) 2016-04-01 2022-06-14 西格诺药品有限公司 Substituted aminopurine compounds, compositions thereof, and related methods of treatment
EP3442535B1 (en) 2016-04-15 2022-06-01 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
BR112018071097B1 (en) 2016-04-15 2024-02-20 Cancer Research Technology Limited HETEROCYCLIC COMPOUND AS RET KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION AND ITS USE
FI3442977T3 (en) 2016-04-15 2023-09-26 Blueprint Medicines Corp Inhibitors of activin receptor-like kinase
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
CN110022900A (en) 2016-09-08 2019-07-16 蓝图药品公司 The combination of fibroblast growth factor receptor 4 inhibitor and cell cycle protein dependent kinase inhibitor
JP2018052878A (en) 2016-09-29 2018-04-05 第一三共株式会社 Pyridine compound
CN106749231B (en) 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 Naphthyridine compounds and pharmaceutical composition and their application
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JP7105774B2 (en) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド Methods for treating cancer
JP6888101B2 (en) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolo [1,5-a] pyrazine compounds as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN110891573A (en) 2017-05-15 2020-03-17 缆图药品公司 Combinations of RET inhibitors and MTORC1 inhibitors and their use for treating cancers mediated by aberrant RET activity
WO2018237134A1 (en) 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (en) 2017-06-30 2019-01-11 厦门大学 Substituted aryl ethers compounds, preparation method, Pharmaceutical composition and its application
EP4095258A1 (en) 2017-07-07 2022-11-30 Nipd Genetics Public Company Limited Target-enriched multiplexed parallel analysis for assesment of tumor biomarkers
PT3728271T (en) 2017-12-19 2022-10-06 Turning Point Therapeutics Inc Macrocyclic compounds for treating disease
TW201932464A (en) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CR20200522A (en) 2018-04-03 2021-02-17 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation EGFR MUTANT CANCER TREATMENT

Also Published As

Publication number Publication date
IL302209B1 (en) 2024-02-01
US10584114B2 (en) 2020-03-10
RS65069B1 (en) 2024-02-29
SI3371171T1 (en) 2024-03-29
US20200407341A1 (en) 2020-12-31
EP4292594A3 (en) 2024-03-27
IL288519A (en) 2022-01-01
IL288519B1 (en) 2023-05-01
FR24C1016I1 (en) 2024-06-28
US10030005B2 (en) 2018-07-24
TW201720809A (en) 2017-06-16
PH12018500907A1 (en) 2018-11-05
PL3371171T3 (en) 2024-03-25
JP2022058976A (en) 2022-04-12
SA518391496B1 (en) 2021-07-26
TW202241870A (en) 2022-11-01
AU2016348402B2 (en) 2021-05-13
IL288519B2 (en) 2023-09-01
TWI757256B (en) 2022-03-11
DK3371171T3 (en) 2023-12-11
EP4331585A2 (en) 2024-03-06
CN111423416B (en) 2023-05-26
BR112018008877A8 (en) 2019-02-26
EA201891087A1 (en) 2018-12-28
MX2018005528A (en) 2018-11-09
IL258902A (en) 2018-06-28
HRP20231681T1 (en) 2024-04-12
ES2969185T3 (en) 2024-05-16
NZ742351A (en) 2023-03-31
CN108473468A (en) 2018-08-31
IL302209A (en) 2023-06-01
EP4292594A2 (en) 2023-12-20
EP3371171A1 (en) 2018-09-12
US20220315560A1 (en) 2022-10-06
KR20180073689A (en) 2018-07-02
BR112018008877B1 (en) 2023-01-24
IL258902B (en) 2022-01-01
CN108473468B (en) 2020-06-16
PT3371171T (en) 2024-01-24
CL2018001181A1 (en) 2018-10-12
FI3371171T3 (en) 2024-01-10
EP4331585A3 (en) 2024-05-15
CA3003721A1 (en) 2017-05-11
AU2016348402A1 (en) 2018-05-31
CN111423416A (en) 2020-07-17
JP6807385B2 (en) 2021-01-06
TWI787018B (en) 2022-12-11
CA3003721C (en) 2024-02-06
JP7026196B2 (en) 2022-02-25
JP2018535967A (en) 2018-12-06
US11279688B2 (en) 2022-03-22
EA038890B1 (en) 2021-11-03
HK1259287A1 (en) 2019-11-29
WO2017079140A1 (en) 2017-05-11
US20170121312A1 (en) 2017-05-04
ZA201803050B (en) 2019-09-25
LT3371171T (en) 2024-01-10
BR112018008877A2 (en) 2018-11-06
JP2021036004A (en) 2021-03-04
HUE064659T2 (en) 2024-04-28
US20240417386A1 (en) 2024-12-19
US20190185454A1 (en) 2019-06-20
EP3371171B1 (en) 2023-10-25
MY194262A (en) 2022-11-25
IL302209B2 (en) 2024-06-01
MX384884B (en) 2025-03-14

Similar Documents

Publication Publication Date Title
IL288519A (en) Inhibitors of ret
IL251584B (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL246902B (en) Dihydropyrrolopyridine inhibitors of ror-gamma
ZA201604272B (en) Inhibitors of glutaminase
SG11201706729SA (en) Derivatives of sobetirome
IL259796A (en) Aza-benzimidazole inhibitors of pad4
IL257061A (en) Inhibitors of ezh2
EP3183255C0 (en) Spiropyrrolidines as mdm2 inhibitors
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
GB201501004D0 (en) Inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
GB201520949D0 (en) Inhibitors
HK40105122A (en) Inhibitors of ret
HUP1500506A2 (en) Salts of palbociclib
MA43165A (en) RET INHIBITORS